From Wikitia
Jump to navigation Jump to search
Native name
Traded as1783
Industrymedical device
Founded3 December 1998; 25 years ago (1998-12-03)
HeadquartersNo.88, Keji 1st Rd., Guishan Dist.,,
Taoyuan City
Area served
Key people
  • Vincent Lin (Chairman)
  • Intra-articular Injection
  • Collagen Based Regenerative Matrix
  • Synthetic Bone Graft
  • Dermal Filler Injection
  • Ophthalmic Viscoelastic
Number of employees
Increase 120 (2023)

Maxigen Biotech Inc. (MBI), founded in 1998 in Taiwan, specialises in biomedical products like medical equipment and consumables, with a focus on collagen and hyaluronic acid. Their offerings include intra-articular injections, synthetic bone grafts, regenerative matrices, dermal fillers, and ophthalmic viscoelastics.

In 2021, MBI became part of the TCI Group and received investment from Formosa Biomedical Technology Corp. MBI also serves various key stakeholders like TCI Bio and NuVasive Inc., and reported revenue exceeding USD20 million in 2022. While currently successful in 22 countries.

With a robust supply chain, R&D efforts, customer diligence, and strategic partnerships that contribute to its resilience, MBI envisions growth as an opportunity to solidify its global standing and emphasise agility. Its focus on innovation, customer-centricity, and financial stability also play a critical role in MBI’s success.


External links

Add External links

This article "MAXIGEN BIOTECH" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.